Antiretroviral therapy coverage in Bahrain
Bahrain: Antiretroviral therapy coverage was 55.0% in 2024. ◆ Volatile
Antiretroviral therapy coverage in Bahrain, 2000–2024
Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of people living with HIV.
Analysis
In 2024, antiretroviral therapy coverage in Bahrain stood at 55.0%.
The figure is up 3.8% on the previous year and up 66.7% over ten years.
Over the whole period, antiretroviral therapy coverage in Bahrain peaked at 64.0% in 2020 and was at its lowest, 7.0%, in 2000.
That places Bahrain 112th out of 143 countries with data for 2024, putting it in the bottom quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Antiretroviral therapy coverage in Bahrain, year by year
| Year | % of people living with HIV | Change |
|---|---|---|
| 2000 | 7.0% | — |
| 2001 | 8.0% | +14.3% |
| 2002 | 12.0% | +50.0% |
| 2003 | 12.0% | +0.0% |
| 2004 | 12.0% | +0.0% |
| 2005 | 15.0% | +25.0% |
| 2006 | 17.0% | +13.3% |
| 2007 | 19.0% | +11.8% |
| 2008 | 20.0% | +5.3% |
| 2009 | 21.0% | +5.0% |
| 2010 | 24.0% | +14.3% |
| 2011 | 28.0% | +16.7% |
| 2012 | 30.0% | +7.1% |
| 2013 | 31.0% | +3.3% |
| 2014 | 33.0% | +6.5% |
| 2015 | 35.0% | +6.1% |
| 2016 | 33.0% | -5.7% |
| 2017 | 35.0% | +6.1% |
| 2018 | 46.0% | +31.4% |
| 2019 | 59.0% | +28.3% |
| 2020 | 64.0% | +8.5% |
| 2021 | 55.0% | -14.1% |
| 2022 | 49.0% | -10.9% |
| 2023 | 53.0% | +8.2% |
| 2024 | 55.0% | +3.8% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 14.3% | 7.0% | 21.0% | 10 |
| 2010s | 35.4% | 24.0% | 59.0% | 10 |
| 2020s | 55.2% | 49.0% | 64.0% | 5 |
Countries ranked near Bahrain
- 109 North Macedonia 59.0% compare
- 110 Paraguay 58.0% compare
- 111 Venezuela, Bolivarian Republic of 57.0% compare
- 112 Syrian Arab Republic 55.0% compare
- 114 Jamaica 54.0% compare
- 115 Kyrgyzstan 53.0% compare
- 115 Republic of Moldova 53.0% compare
More health data for Bahrain
- Un projection of annual infant deaths, annual growth rate 0 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.4635 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 476.9 deaths per 1,000 people (2090)
- Number of infants who die before age 1 41 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate 0.6427 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0292 units per person (2025)
- Population ages 00-04, male, annual growth rate 0.2418 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is antiretroviral therapy coverage in Bahrain?
- Antiretroviral therapy coverage in Bahrain was 55.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
- What is the highest antiretroviral therapy coverage recorded in Bahrain?
- The highest recorded value was 64.0% in 2020.
- What is the lowest antiretroviral therapy coverage recorded in Bahrain?
- The lowest recorded value was 7.0% in 2000.
- How does Bahrain rank for antiretroviral therapy coverage?
- Bahrain ranks 112th out of 143 countries with data for 2024.
- Is antiretroviral therapy coverage rising or falling in Bahrain?
- Over the last ten years it is up 66.7%. The long-run trend across the full record is volatile.
- Where does this Bahrain data come from?
- The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage (% of people living with HIV). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.